Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenna Jacobson

Physician Assistant Parker, CO Physician Assistant

NPI 1548650450 CMS profile 10590461

9403 Crown Crest Blvd Ste 300Im, Parker, CO 80138

Open in the dashboard

General payments

$3,568

193 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Jacobson of Parker, CO is reported in the CMS Open Payments database as having received $3,568 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $346 20
2024 General $320 17
2023 General $1,091 54
2022 General $1,048 58
2021 General $764 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Jacobson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jenna Jacobson were reported at $346. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jenna Jacobson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $764 $132 $37–$438 $132
2022 $1,048 $155 $48–$522 $149
2023 $1,091 $167 $52–$557 $160
2024 $320 $178 $55–$600 $164
2025 $346 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $545 34 payments
  2. AstraZeneca Pharmaceuticals LP $455 27 payments
  3. Novo Nordisk Inc $307 15 payments
  4. AbbVie, Inc. $259 13 payments
  5. Amgen Inc. $227 13 payments
  6. Novartis Pharmaceuticals Corporation $195 10 payments
  7. Astellas Pharma US Inc $192 5 payments
  8. Exact Sciences Corporation $181 8 payments
  9. Lilly USA, LLC $166 12 payments
  10. GlaxoSmithKline, LLC. $139 8 payments
  11. Other $902 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,462 191 payments
  2. Education $106 2 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $329 20 payments
  2. ELIQUIS $264 16 payments
  3. Repatha $210 12 payments
  4. Cologuard Collection Kit $181 8 payments
  5. PAXLOVID $175 11 payments
  6. ENTRESTO $173 9 payments
  7. Ozempic $161 8 payments
  8. RYBELSUS $161 8 payments
  9. COMIRNATY $160 10 payments
  10. Otezla $155 9 payments
  11. Other $3,032 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,408

Median for Physician Assistant: 241

Drug cost

$189,018

Median for Physician Assistant: $4,110

Branded share of claims

20%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 46 $70,033
Repatha Sureclick Evolocumab Brand 26 $29,371
Jardiance Empagliflozin Brand 20 $28,636
Eliquis Apixaban Brand 15 $17,839
Mounjaro Tirzepatide Brand 13 $13,877
Rosuvastatin Calcium Generic 105 $1,953
Albuterol Sulfate Hfa Albuterol Sulfate Brand 54 $1,819
Synthroid Levothyroxine Sodium Brand 27 $1,806
Estradiol Generic 26 $1,482
Solifenacin Succinate Generic 14 $1,327

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$38,116

Of which drugs: $7,340

Medicare patients

313

Average age 75

Services billed

775

197 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 56%
Ischemic heart disease 30%
Osteoporosis 23%
Chronic kidney disease 20%
Diabetes 19%
Depression 19%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 22 22 $6,398

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REBLOZYL
  • Celgene Corporation $30
$30 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $22
$22 — —
NURTEC ODT
  • PFIZER INC. $22
$22 — —
QULIPTA
  • AbbVie, Inc. $20
$20 — —
Otezla
  • Amgen Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record